To find a more efficient way to diagnose csPCA and avoid unnecessary biopsy, in our study, we collected the methylation data for two sites on the PRKY promoter (cg05618150 and cg05163709) in blood samples and MRI data from csPCA and ncsPCA or benign prostatic hyperplasia patients to determine the combined relevance of these data with PCa of different ISUP grades. The gene discussed is PRKY; the disease is posterior cortical atrophy.